The Journal of Intellectual Property Law and Practice has published an article by partner Darren Smyth about the judgement in Eli Lilly & Company v Janssen Alzheimer Immunotherapy.
Mr Justice Arnold determines that a patent directed towards antibodies to ß-amyloid peptide, for the treatment of Alzheimer's disease, is invalid for insufficiency.
To read the JIPLP article in full, click here.